# Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

> **NCT00240422** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 96 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Hypertension

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT00240422
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2013-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240422, "Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00240422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*